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recurrence and 15 patients had bilateral recurrence, median time
to recurrence was 3.2 years and median follow-up time was
6.2 years. A weak correlation was observed between cytoplasmic
pAkt and cytoplasmic pNF-kB (cc 0.166, P = 0.001). Cytoplasmic
pAkt expressionwas associatedwith decreased time to recurrence
(p = 0.025) and was significantly higher in ER negative tumours
compared to ER positive (p = 0.004). When cohort was split by PR
status, the associationwith decreased time to recurrence and cyto-
plasmicpAktwaspotentiated (p = 0.008).CytoplasmicpAktexpres-
sioncorrelatedsignificantlywithnuclearpAktexpression (cc0.696,
p < 0.001). Nuclear pAkt expression was also associated with
decreased time to recurrence (p = 0.043). In addition the observa-
tion with nuclear pAkt was potentiated in ER negative tumours
(p = 0.037) andPRnegative tumours (p = 0.002). No significant corre-
lation with time to recurrence was observed for NF-kB or pNF-kB.
Conclusion: In the current cohort pAkt expression was associ-
ated with recurrence, however this was independent of the NF-
kB cascade.
doi:10.1016/j.ejcsup.2010.06.015
O-15 UPREGULATION OF THE ESTROGEN PATHWAY IN ENDO-
CRINE SENSITIVE BREAST CANCER CELLS WITH HERCEPTIN
TREATMENT
J.G. Solon, D. Collins, M. McIlroy, A.D.K. Hill, L. Young. Endocrine
Oncology Research Group, Royal College of Surgeons in Ireland, Ireland
Breast cancer is the leading cause of cancer-related deaths in
women in Ireland. Receptor crosstalk has been implicated in the
development of resistance to therapies and cancer relapse. We
have previously shown that treatment of endocrine insensitive
or independent breast cancer cells with herceptin repressed tran-
scriptional activity of the oncogene c-Myc through SMRT activity.
However, endocrine sensitive breast cancer cells with low levels
of HER2 receptor showed hyperactivation of the estrogen/steroid
pathway through recruitment of the cointegrator protein CBP.
The aim of this study was to demonstrate the activation of the
steroid pathway in endocrine sensitive breast cancer cells treated
with herceptin using the classical ER target gene pS2 as a marker
of activity.
MCF-7cells (highER, lowHER2, endocrinedependent) andLCC-1
cells (highER,highHER2, endocrine independent)were treatedwith
estradiol (E2), tamoxifen and herceptin. Semi-quantitative RT-PCR
and qRT- PCR was performed to quantify pS2 mRNA levels. The
impact of treatments on pS2 promoter activity was then assessed.
Cells were transfected with the expression vector pSG5- ERa and
the luciferse reporter plasmid pGL3-pS2 promoter and the level of
transcriptional activity recorded. Increases in pS2 mRNA were
found inMCF-7 cells treatedwithherceptinbutnot LCC-1 cells. This
was replicated at a transcriptional level through luciferase assay.
We have shown that at mRNA and transcriptional levels treat-
ment of MCF-7 cells with herceptin results in upregulation of the
steroid pathway. We are currently conducting further molecular
studies to further elucidate the signalling pathways involved.
doi:10.1016/j.ejcsup.2010.06.016
O-16 JAMA-A: A HOPE FOR BREAST CANCER THERAPY?
Gozie Offiah. Department of Surgery, Royal College of Surgeons,
Ireland
Background: Breast cancer is a very prevalent disease with
most cancers originating in the milk ducts, composed of a layer
of polarized epithelial cells. Loss of polarity is a hallmark of
many cancers including breast. We recently showed a novel
correlation between over-expression of the cell adhesion pro-
tein JAM-A and poor prognosis in invasive breast cancer
patients.1
Aim: To determine whether JAM-A regulates proliferation and
polarity in breast cancer cells in a manner explaining its associa-
tion with aggressive cancer phenotypes.
Materials and methods: Proliferation assays were carried out
using the isogenic breast cancer cell line series HMT-3522, of S1
(normal) and T42 (invasive) cells in the presence of an inhibitory
JAM-A antibody. Both cell types were grown in a 3-dimensional
(3D) extracellular matrix culture model. Cultures were exposed
to inhibitory JAM-A antibody to determine the consequences
of antagonising JAM-A function for 3D polarization and
differentiation.
Results: We observed significant anti-proliferative effects in
both S1 and T42 cells exposed to JAM-A inhibitory antibody over
time. Both S1 and T42 cells treated with JAM-A inhibitory anti-
body showed significant reductions in 3D spheroidal diameter rel-
ative to IgG-treated cells (p < 0.05), correlating with observed anti-
proliferative effect. Furthermore, invasive T4-2 cells in 3D culture
treated with JAM-A inhibitory antibody exhibited a partial nor-
malization of phenotype.
Conclusions: Our results indicate that JAM-A inhibition
decreases proliferation and promotes polarisation. Therefore,
we speculate that pharmacological antagonism of JAM-A in
breast cancer patients may offer a novel therapeutic opportunity.
Reference:
1. McSherry EA, McGee SF, Jirstrom K, Doyle EM, Brennan DJ,
Landberg G, et al. JAM-A expression positively correlates with
poor prognosis in breast cancer patients. Int J Cancer
2009;125(6):1343–51.
doi:10.1016/j.ejcsup.2010.06.017
O-17 BORDERLINE HER2 PROTEIN POSITIVE BREAST CANCERS
HAVE SIMILAR PATIENT OUTCOME REGARDLESS OF HER2 GENE
AMPLIFICATION STATUS
F.F.T. Barros, M. Aleskandarany, E. Rakha, S.L. Watts, D.G. Powe,
I.O. Ellis, A.R. Green. Division of Pathology, Nottingham University
Hospitals and University of Nottingham, Nottingham, UK
HER2 plays an important role in breast cancer progression and
provides predictive and prognostic information. However, prog-
nostic information provided by IHC expression categories and
prognostic value added by using in situ hybridisation (ISH) in bor-
derline cases remains unclear.
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We have assessed HER2 status in a large well-characterised
breast cancer series prepared as tissue microarray (n = 1858) using
IHC (HercepTest, DakoCytomation) and chromogenic ISH (CISH;
DuoCISH, DakoCytomation) in order to identify relationships with
clinico-pathological variables and patient outcome. None of these
cases have received anti-HER2 therapy.
There was excellent overall concordance between HercepTest
negative (scores 0/1+) and positive (3+) with CISH positive/nega-
tive (defined as HER2/Chr17 copy number ratio of P2; p < 0.001).
Twelve percent of cases were identified as HER2 positive (those
with 3+ HercepTest scores or 2+ with gene amplification). Of the
74 borderline HercepTest 2+ cases, 44 cases (59%) showed HER2
gene amplification. We identified that HercepTest 2+ non-ampli-
fied cases were not significantly different from those amplified
2+ or 3+ cases with respect to their clinical outcome (BCSS and
DFS).
The overall concordance between HercepTest and CISH analy-
sis for HER2 status was excellent. All HercepTest 2+ cases identi-
fied were observed to have poor outcomes similar to those
HercepTest 3+ cases regardless of gene amplification status. In
the current clinical environment, cases exhibiting IHC 2+ with
non-amplified HER2 gene status are not offered targeted HER2
therapy but do exhibit aggressive clinical behavioural characteris-
tics and therefore optimal treatment strategies for these patients
need to be determined.
doi:10.1016/j.ejcsup.2010.06.018
O-18 PARP1 EXPRESSION IN HORMONE ESTROGEN RECEPTOR
NEGATIVE BREAST CANCER: PREFERENTIAL EXPRESSION IN
BASAL-LIKE AND HER2-POSITIVE TUMOURS
Ahmed A. Benhasouna, Andrew R. Green, Des G. Powe,
Muhammad A. Aleskandarany, Emad A. Rakha, Ian O.
Ellis. Division of Pathology, Nottingham University Hospitals and
University of Nottingham, Nottingham, UK
Nuclear poly (ADP-ribose) polymerases (PARPs) are a family of
global monitor of chromatin structure and DNA damage repair.
The relative expression levels of PARP1 protein in estrogen recep-
tor negative (ER–ve) BC remain unclear. Therefore the aim of this
study was to investigate PARP1 protein expression in ER–ve BC
with relevance to molecular subtypes and disease outcome.
Methods: PARP1 protein expression was assessed, using immu-
nohistochemistry, in a well-characterised series of ER–ve primary
operable invasive BC cases (n = 251) with long term clinical follow-
up. Results were correlated with molecular and clinicopathologi-
cal parameters and patients’ outcome.
Results: PARP1 nuclear expression was classified as high or low
using a cut-off of 80 H-score, determined using X-Tile bio-infor-
matics software. One hundred and thirty five (53.8%) of the infor-
mative cases were classified showing high expression. Significant
positive correlation was found between PARP1 expression and
BRCA1 expression (p = 0.002) but no association was found with
p53. High PARP1 expression was observed in both basal-like
(HER2– and CK5/6 and or EGFR+) (60%) and HER2+ (64%) compared
with triple negative (TN) non-basal BC classes (45%). PARP1
expression was significantly associated with BC specific survival
(p = 0.01). When analysis was assessed by the molecular subtype,
the association of PARP1 expression with improved survival was
restricted to TN tumours.
Conclusion: We have observed a positive correlation between
PARP1 protein expression and BRCA1 expression. Although high
PARP1 expression is seen in ER–/HER+ and HER– tumours, its
association with survival was only found in the ER–/HER2– sub-
type. Thus, its targeted inhibition may particularly benefit
patients with TN BC.
doi:10.1016/j.ejcsup.2010.06.019
O-19 COMPARISON OF IMPUTATION METHODS FOR MISSING
IMMUNOHISTOCHEMICAL MARKERS IN A STUDY OF BREAST
CANCER PROGNOSIS
Alaa M.G. Ali a, S.-J. Dawson b,c, F. Blows b, E. Provenzano c,d,e, C.
Caldas b,c,d,e, Paul Pharoah a,b. aDepartment of Public Health and
Primary Care, Cambridge, UK. bDepartment of Oncology, University of
Cambridge, Cambridge, UK. cCancer Research UK Cambridge Research
Institute, Cambridge, UK. dCambridge Breast Unit, Addenbrooke’s
Hospital, Cambridge, UK. eNIHR Cambridge Biomedical Research
Centre, Cambridge, UK
Background: Tissue micro-arrays (TMA) are increasingly used to
generate data for studies of tumourmolecular phenotypehowever,
TMA data are particularly prone tomissingness. Avariety ofmeth-
ods to deal withmissing data are available; these have been exten-
sively evaluated using simulated data, but there has been no
empirical evaluations of these methods using real TMA data.
Methods: We pooled data from over 11,000 cases of invasive
breast cancer from five studies that collected information on
seven prognostic indicators including four molecular markers,
together with survival time data. We compared the results of a
multi-variate Cox regression using complete case analysis
(CCA), mean substitution (MS) and multiple imputation (MI). We
also performed an analysis in which missing data were simulated
under different assumptions.
Results: Over half the cases had data on at least one of the
seven variables and 10.5% had missing data on 4 or more. The
hazard ratio estimates based on multiple imputation and mean
substitution, were similar with similar standard errors. Hazard
ratio estimates and confidence intervals (Table). The results from
CCA were less precise (wider confidence limits). Accuracy of the
estimates was based on the simulated data with CCA having
the least accurate results.
Hazard ratios and confidence intervals using mean substitution
and multiple imputation.
Method ER status PR status HER2 status BCL2 status
Multiple
imputation
– HR (CIs)
0.43
(.35–54)
0.39
(.30–.50)
1.25
(1.13–1.40)
0.85
(.76–.96)
Mean
substitution
– HR (CIs)
0.40
(.32–.49)
0.37
(.29–.46)
1.31
(1.17–1.46)
0.82
(.74–.92)
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